Imagion Biosystems Ltd. (IBX) AI Stock Analysis

• Market Cap: AU$2.21M
• Dividend Yield: N/A
• Average Volume (3M): 326.91K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.11
• Revenue Growth: 55.07%
• EPS Growth: 88.20%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 201,341,420
• 10 Day Avg. Volume: 530,118
• 30 Day Avg. Volume: 326,912
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The overall stock score reflects the significant financial challenges faced by Imagion Biosystems Ltd., including negative equity and cash flow issues. Technical analysis further indicates bearish momentum, and valuation metrics highlight concerns over profitability. These factors combine to create a low overall score.

Imagion Biosystems Ltd. Business Overview & Revenue Model

Company Description

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT's novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.

How the Company Makes Money

Imagion Biosystems makes money primarily through the development and commercialization of its MagSense™ technology. The company generates revenue by partnering with healthcare institutions, research organizations, and pharmaceutical companies to integrate its imaging solutions into clinical and research settings. Revenue streams include licensing agreements, collaboration fees, and potential sales of diagnostic imaging products. The company may also receive funding through grants and strategic partnerships that support the research and development of its diagnostic technologies. Additionally, Imagion Biosystems may pursue revenue through the commercialization of future products and applications derived from its core technology.

Imagion Biosystems Ltd. Financial Statement Overview

Summary

Imagion Biosystems Ltd. shows strong revenue growth but faces profitability and financial stability challenges. Negative equity and high leverage pose significant risks, while negative cash flows indicate sustainability concerns.

Income Statement

The company shows substantial revenue growth, with a 94.9% increase from the previous period, indicating strong top-line expansion. However, persistent negative net income and EBIT margins suggest ongoing challenges in achieving profitability. The gross profit margin has improved significantly but remains under pressure, indicating cost management issues.

Balance Sheet

The balance sheet reveals a concerning negative equity position, indicating financial instability. High debt levels relative to equity suggest significant leverage risks. Despite these issues, the company has managed to maintain cash reserves, albeit declining over time, reflecting potential liquidity challenges.

Cash Flow

Operating cash flow remains negative, highlighting difficulties in generating cash from core operations. While there is a notable improvement in free cash flow, it still remains negative, reflecting ongoing cash burn. The reliance on financing cash flows to sustain operations indicates potential sustainability issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.67M	1.37M	473.43K	232.87K	205.72K
Gross Profit	2.26M	-3.88M	-3.14M	-2.47M	-2.66M
EBITDA	-700.09K	-10.30M	-9.49M	-5.90M	-5.19M
Net Income	-2.07M	-12.47M	-9.81M	-8.64M	-7.80M
Balance Sheet
Total Assets	2.80M	4.59M	9.98M	14.12M	14.12M
Cash, Cash Equivalents and Short-Term Investments	2.67M	227.08K	4.45M	13.39M	13.20M
Total Debt	2.85M	6.04M	4.60M	46.02K	660.98K
Total Liabilities	5.09M	8.37M	5.30M	809.88K	1.21M
Stockholders Equity	-2.28M	-3.79M	4.68M	13.31M	12.91M
Cash Flow
Free Cash Flow	-1.27M	-8.51M	-9.21M	-5.29M	-4.63M
Operating Cash Flow	-1.27M	-8.32M	-8.70M	-5.07M	-4.62M
Investing Cash Flow	83.74K	-190.38K	-468.73K	-310.09K	-7.86K
Financing Cash Flow	3.61M	4.29M	-962.06K	5.15M	14.52M

Imagion Biosystems Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IBX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, above the 50-day MA of <0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 21.16 is Positive, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IBX.

Imagion Biosystems Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	69 Neutral	AU$36.36M	19.87	87.09%	2.68%	1.86%	16.10%
Sector *	49 Neutral	AU$2.53B	3.19	-57.47%	2.77%	36.73%	13.67%
BDX	46 Neutral	AU$24.15M	―	-104.23%	―	―	-17.26%
LDX	43 Neutral	AU$20.96M	―	-51.49%	―	80.84%	57.59%
IBX	42 Neutral	AU$2.21M	―		―	55.07%	88.20%
WFL		AU$1.48M	―		―	―	―
IIQ	43 Neutral	AU$41.30M	―	-39.07%	―	26.07%	0.85%

Imagion Biosystems Ltd. Corporate Events

Imagion Biosystems to Present at Landmark Venture Forum

Imagion Biosystems announced its participation in the Landmark Venture Forum, a prestigious event limited to select investors and guests. The company’s Chief Business Officer, Ward Detwiler, will present on their groundbreaking molecular magnetic resonance imaging technology, which could significantly impact the early detection of cancer, potentially improving Imagion’s industry positioning and offering promising implications for stakeholders.

Imagion Biosystems Relocates Office to Enhance Operations

Imagion Biosystems has announced a change in its registered office and principal place of business to a new address in Melbourne, while maintaining the same contact details. This move signifies a strategic step in its operations, potentially enhancing its business functions and stakeholder engagement.

Imagion Biosystems Ltd. AGM Results: All Resolutions Carried

Imagion Biosystems Ltd. announced the results of its Annual General Meeting held on May 30, 2025, where all resolutions were carried. Key resolutions included the adoption of the remuneration report, re-election of Brett Mitchell as a director, and the approval of options issuance to key personnel and entities. The successful passage of these resolutions reflects shareholder support for the company’s strategic direction and governance, potentially strengthening its market position and operational capabilities.

Imagion Biosystems Advances Cancer Detection Programs

Imagion Biosystems has provided a business update ahead of its Annual General Meeting, highlighting the progress of its MagSense® HER2 Imaging Agent for HER2+ breast cancer. The company plans to begin manufacturing the imaging agent in June and aims to file an Investigational New Drug application with the FDA for a Phase 2 study in the third quarter of 2025. The company has engaged with the FDA for feedback and identified a Principal Investigator for the study. Additionally, Imagion is optimizing MRI protocols in collaboration with Siemens and Wayne State University. The company is also preparing to restart its prostate and ovarian cancer programs, with Dr. Kayat-Bittencourt joining as a clinical advisor for the prostate cancer program.

Imagion Biosystems to Hold Virtual AGM on May 30, 2025

Imagion Biosystems Limited has announced that its Annual General Meeting (AGM) will be held virtually on May 30, 2025. Shareholders are encouraged to access meeting materials online and submit their proxy votes ahead of the meeting. The virtual format allows shareholders to participate by asking questions and voting on resolutions, ensuring engagement despite the lack of a physical gathering.

Imagion Biosystems Advances Cancer Imaging Program with Upcoming IND Filing

Imagion Biosystems has released its quarterly activity report for Q1 FY2025, highlighting progress in its MagSense® HER2 breast cancer imaging agent program. The company is preparing to file an Investigational New Drug (IND) application with the U.S. FDA, which would enable the next phase of clinical studies. Manufacturing of the imaging agent is underway, and discussions with leading hospitals and cancer centers in the U.S. are ongoing. The company expects to file the IND in the third quarter and begin the Phase 2 study in the latter half of the year. Additionally, research and development for prostate and ovarian cancer programs are anticipated to commence later in the year, contingent on funding. The company reported a cash balance of AU$1.71 million at the end of March 2025, with increased operating cash outflows due to R&D expenditures.